TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27142472

Group type: EXPERIMENTAL
Intervention: Arsenic trioxide (ASO) administered as an intravenous infusion over 1-2 hours daily for 4 days in week 1 and for 2 days in weeks 2-6 of an 8-week cycle.
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Cisplatin (3 mg/kg i.p. weekly) tested in PDX derived from platinum-sensitive SCLC.
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Cisplatin (3 mg/kg i.p. weekly) tested in PDX derived from platinum-refractory SCLC.
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Patient-derived xenografts (PDX) grown from transplanted biopsy samples.
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Arsenic trioxide (ASO) in vitro efficacy.
Number of subjects: 17
Study: 27142672

Group type: EXPERIMENTAL
Intervention: Hypocaloric hyperproteic diet (HHD), ~1000 kcal/day, ~125 g protein/day for 3 weeks
Number of subjects: 15
Study: 27143353

Group type: EXPERIMENTAL
Intervention: Leptin antagonist applied locally to the ascending aorta in AngII-infused mice.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Exogenous leptin applied on the surface of the ascending aorta.
Number of subjects: 0
Study: 27143668

Group type: EXPERIMENTAL
Intervention: HIV-1-infected individuals
Number of subjects: 527

Group type: COMPARATOR
Intervention: HIV-negative controls
Number of subjects: 527

Group type: EXPERIMENTAL
Intervention: HIV-1-infected individuals with prior stavudine exposure
Number of subjects: 527
Study: 27143789

Group type: EXPERIMENTAL
Intervention: Anakinra
Number of subjects: 43
Study: 27144169

Group type: EXPERIMENTAL
Intervention: Arm crank ergometry (ACE)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Wheelchair ergometry (WCE)
Number of subjects: 12
Study: 27145169

Group type: EXPERIMENTAL
Intervention: Emergency abdominal surgery in high-HDI countries
Number of subjects: 10745

Group type: EXPERIMENTAL
Intervention: Emergency abdominal surgery in middle-HDI countries
Number of subjects: 10745

Group type: EXPERIMENTAL
Intervention: Emergency abdominal surgery in low-HDI countries
Number of subjects: 10745

Group type: EXPERIMENTAL
Intervention: Use of surgical safety checklist in low- and middle-income countries
Number of subjects: 10745

Group type: COMPARATOR
Intervention: Emergency abdominal surgery in middle-income countries
Number of subjects: 10745

Group type: COMPARATOR
Intervention: Emergency abdominal surgery in low-income countries
Number of subjects: 10745
Study: 27145310

Group type: EXPERIMENTAL
Intervention: Symptomatic treatment (nonantibiotic) consisting of mild analgesics (nonsteroidal anti-inflammatory drug or paracetamol)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Symptomatic treatment (nonantibiotic)
Number of subjects: 161
Study: 27145749

Group type: EXPERIMENTAL
Intervention: EWA algorithm (Expectation Maximization, weighted intensity, a priori information)
Number of subjects: 124
Study: 27145999

Group type: EXPERIMENTAL
Intervention: Hib-MenC-TT vaccine coadministered with DTPa-based combination vaccines and pneumococcal conjugate vaccine.
Number of subjects: 530

Group type: COMPARATOR
Intervention: Control MenC conjugate vaccine coadministered with DTPa-based combination vaccines and pneumococcal conjugate vaccine.
Number of subjects: 530

Group type: EXPERIMENTAL
Intervention: All groups (including both Hib-MenC-TT and control)
Number of subjects: 530
Study: 27146407

Group type: EXPERIMENTAL
Intervention: Unacylated ghrelin (UAG) levels in infants with PWS
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Acylated ghrelin (AG) levels in infants with PWS
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: AG/UAG ratio in infants with PWS
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (age-matched controls without endocrine disorder)
Number of subjects: 37
Study: 27146511

Group type: EXPERIMENTAL
Intervention: Genomic information in the anger condition
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Genomic information
Number of subjects: 190
Study: 27146652

Group type: EXPERIMENTAL
Intervention: COPD patients
Number of subjects: 23

Group type: COMPARATOR
Intervention: Healthy older adults (control group)
Number of subjects: 23
Study: 27146701

Group type: EXPERIMENTAL
Intervention: Implants (10,096 total)
Number of subjects: 2670

Group type: COMPARATOR
Intervention: Smoking
Number of subjects: 2670

Group type: COMPARATOR
Intervention: Antidepressants intake
Number of subjects: 2670
Study: 27146799

Group type: EXPERIMENTAL
Intervention: Exenatide Once Weekly (QW)
Number of subjects: 129
Study: 27147390

Group type: EXPERIMENTAL
Intervention: Clinical prediction rule based on ECG, BNP levels, and other biomarkers
Number of subjects: 1959

Group type: EXPERIMENTAL
Intervention: Follow-up of patients' cohort
Number of subjects: 1959
Study: 27147615

Group type: EXPERIMENTAL
Intervention: Self-reported sexual abstinence
Number of subjects: 715

Group type: EXPERIMENTAL
Intervention: Item non-response regarding sexual behaviour
Number of subjects: 715

Group type: EXPERIMENTAL
Intervention: Self-reported abstinence with item non-response
Number of subjects: 715
Study: 27147905

Group type: EXPERIMENTAL
Intervention: Nurse-led patient education program
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no education)
Number of subjects: 26
Study: 27148068

Group type: EXPERIMENTAL
Intervention: BAT+ group
Number of subjects: 18
Study: 27148134

Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMDR)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Relaxation Therapy (RT)
Number of subjects: 42
Study: 27148452

Group type: EXPERIMENTAL
Intervention: CC-486 (300 mg once daily for the first 21 days of 28-day treatment cycles)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (once daily for the first 21 days of 28-day treatment cycles)
Number of subjects: 0
Study: 27148765

Group type: EXPERIMENTAL
Intervention: Mean Daytime Activity (MDTA)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Sleep Quality (PSQI)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: FACIT-F
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Overall Survival (OS)
Number of subjects: 79
Study: 27149016

Group type: EXPERIMENTAL
Intervention: Arm positioned in 90° abduction
Number of subjects: 49

Group type: COMPARATOR
Intervention: Neutral position (control)
Number of subjects: 49
Study: 27149114

Group type: EXPERIMENTAL
Intervention: PPV23 (23-valent pneumococcal polysaccharide vaccine) administered intramuscularly as a single dose
Number of subjects: 100
Study: 27149252

Group type: EXPERIMENTAL
Intervention: E1 (previously calculated equation for estimating fat-free mass)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: New predictive equation
Number of subjects: 155
Study: 27149268

Group type: EXPERIMENTAL
Intervention: eABR measurements with stimulation by a single electrode at 70% of the dynamic range, followed by a summation of these four eABRs
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Measurement of a single eABR with stimulation from all four electrodes at 70% of the dynamic range
Number of subjects: 16
Study: 27149298

Group type: EXPERIMENTAL
Intervention: Ceritinib
Number of subjects: 0
Study: 27149635

Group type: EXPERIMENTAL
Intervention: Patients with PAD during pain-free walking
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control subjects (nondisabled age-matched)
Number of subjects: 61
Study: 27149955

Group type: EXPERIMENTAL
Intervention: CFS patients
Number of subjects: 120

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 120
Study: 27150464

Group type: EXPERIMENTAL
Intervention: Lithium monotherapy
Number of subjects: 700

Group type: COMPARATOR
Intervention: Valproic acid (VPA) or treatment as usual (TAU)
Number of subjects: 700
Study: 27150686

Group type: EXPERIMENTAL
Intervention: H2 receptor antagonists (H2RAs) used by 313 participants
Number of subjects: 6378

Group type: EXPERIMENTAL
Intervention: H2 receptor antagonists (H2RAs)
Number of subjects: 6378

Group type: COMPARATOR
Intervention: Non-use of H2 receptor antagonists (H2RAs)
Number of subjects: 6378
Study: 27150693

Group type: EXPERIMENTAL
Intervention: Dabigatran Etexilate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Idarucizumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Redosing Idarucizumab
Number of subjects: 0
Study: 27151157

Group type: COMPARATOR
Intervention: TAS-102
Number of subjects: 30
Study: 27151347

Group type: EXPERIMENTAL
Intervention: Biventricular pacing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Right ventricular pacing
Number of subjects: 0
Study: 27151607

Group type: EXPERIMENTAL
Intervention: Edwards Sapien
Number of subjects: 848

Group type: EXPERIMENTAL
Intervention: Medtronic CoreValve
Number of subjects: 848

Group type: EXPERIMENTAL
Intervention: TAVR (both devices)
Number of subjects: 848
Study: 27151609

Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloons
Number of subjects: 105
Study: 27151914

Group type: EXPERIMENTAL
Intervention: Cell-assisted lipotransfer using freshly isolated autologous adipose-derived stromal cells (4.07 × 10(7) cells with 10 ml of lipoaspirate)
Number of subjects: 1
Study: 27151994

Group type: EXPERIMENTAL
Intervention: Entinostat (10 or 15 mg oral entinostat once every other week)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Entinostat (15 mg oral entinostat once weekly in 3 of 4 weeks)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Entinostat
Number of subjects: 49
Study: 27152482

Group type: COMPARATOR
Intervention: Montelukast (placebo-controlled trial)
Number of subjects: 343
Study: 27152501

Group type: EXPERIMENTAL
Intervention: MenACWY-TT
Number of subjects: 539

Group type: COMPARATOR
Intervention: Men-PS
Number of subjects: 539
Study: 27152857

Group type: EXPERIMENTAL
Intervention: Chemotherapy during radiation for PET nonresponders who changed chemotherapy (38 patients)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Chemotherapy during radiation for PET responders (113 patients)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Chemotherapy during radiation for PET nonresponders who did not change chemotherapy (50 patients)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: PET responders (113 patients)
Number of subjects: 201

Group type: COMPARATOR
Intervention: PET nonresponders who did not change chemotherapy (50 patients)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: PET nonresponders who changed chemotherapy (38 patients)
Number of subjects: 201
Study: 27153166

Group type: EXPERIMENTAL
Intervention: Autologous peripheral nerve graft implantation
Number of subjects: 8
Study: 27153246

Group type: EXPERIMENTAL
Intervention: faldaprevir 120 mg q.d. for 12 or 24 weeks plus PegIFNα-2b/RBV for 24 or 48 weeks
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: faldaprevir 240 mg q.d. for 12 weeks plus PegIFNα-2b/RBV for 24 or 48 weeks
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: faldaprevir 240 mg q.d. for 24 weeks plus PegIFNα-2b/RBV for 24 or 48 weeks
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: faldaprevir 240 mg q.d. for 24 weeks plus PegIFNα-2b/RBV for 48 weeks
Number of subjects: 131

Group type: COMPARATOR
Intervention: faldaprevir 120 mg q.d. plus PegIFNα-2b/RBV
Number of subjects: 131
Study: 27153752

Group type: EXPERIMENTAL
Intervention: EHR patient portal message promoting influenza vaccines and offering online appointment scheduling
Number of subjects: 30000

Group type: EXPERIMENTAL
Intervention: IVR call with similar content but without appointment facilitation
Number of subjects: 30000

Group type: EXPERIMENTAL
Intervention: Both EHR patient portal message and IVR call
Number of subjects: 30000

Group type: COMPARATOR
Intervention: Neither EHR patient portal message nor IVR call (usual care)
Number of subjects: 30000
Study: 27154507

Group type: EXPERIMENTAL
Intervention: Self-reported questionnaires at 1 week, and 1, 3, 6, 12, and 24 months after injury.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mixed models analysis.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Outcome prediction model development.
Number of subjects: 0
Study: 27154719

Group type: EXPERIMENTAL
Intervention: Activated protein C (DAA) 24 mg/kg/h for 96 h
Number of subjects: 1241

Group type: EXPERIMENTAL
Intervention: Hydrocortisone 50 mg intravenous bolus q6 for 7 days
Number of subjects: 1241

Group type: EXPERIMENTAL
Intervention: Fludrocortisone 50 µg once daily for 7 days
Number of subjects: 1241

Group type: EXPERIMENTAL
Intervention: Combination of DAA and corticosteroids
Number of subjects: 1241

Group type: COMPARATOR
Intervention: Placebo for DAA
Number of subjects: 1241

Group type: COMPARATOR
Intervention: Placebo for corticosteroids
Number of subjects: 1241
Study: 27154907

Group type: EXPERIMENTAL
Intervention: Project SEARCH plus Autism Spectrum Disorder Supports
Number of subjects: 49

Group type: COMPARATOR
Intervention: High school special education services as usual
Number of subjects: 49
Study: 27154915

Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin plus R-CVP (rituximab, cyclophosphamide, vincristine, and prednisone)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin plus R-CVP
Number of subjects: 48
Study: 27154971

Group type: EXPERIMENTAL
Intervention: Current smoking defined using both self-report and eCO concentrations
Number of subjects: 573

Group type: COMPARATOR
Intervention: Current smoking defined using self-report or eCO
Number of subjects: 573
Study: 27155023

Group type: EXPERIMENTAL
Intervention: Citalopram treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 27156227

Group type: EXPERIMENTAL
Intervention: Onalespib (AT13387) 150-220 mg/m² once-weekly intravenous for 3 weeks and imatinib 400 mg daily
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Onalespib (AT13387) plus imatinib
Number of subjects: 26
Study: 27157491

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (10 mg/kg intravenously every 2 weeks for 24 months)
Number of subjects: 39
Study: 27158500

Group type: EXPERIMENTAL
Intervention: CHO-KLAT2.0 (youth)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: SF-36 Physical Component Summary (PCS) (youth)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: SF-36 Mental Component Summary (MCS) (youth)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Haemo-QoL-A (young adults)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: SF-36 Physical Component Summary (PCS) (young adults)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: SF-36 Mental Component Summary (MCS) (young adults)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Joint status as assessed by HJHS
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: History of lifelong prophylaxis
Number of subjects: 46
Study: 27158520

Group type: EXPERIMENTAL
Intervention: Optimized glycemic control (OPT group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Non-optimized glycemic control (non-OPT group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 27158544

Group type: EXPERIMENTAL
Intervention: PEG 3350 17 g once daily for 7 days
Number of subjects: 203

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203
Study: 27159194

Group type: EXPERIMENTAL
Intervention: 5% protein diet (low protein)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 15% protein diet (normal protein)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 25% protein diet (high protein)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (baseline measurements)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Overall effect of overfeeding (all protein levels)
Number of subjects: 20
Study: 27160012

Group type: EXPERIMENTAL
Intervention: Bone marrow mesenchymal stromal cells (MSC) infused into the cerebral arteries.
Number of subjects: 5
Study: 27160286

Group type: EXPERIMENTAL
Intervention: UGT1A1*6, UGT1A1*28, rs1800469 and rs3087465
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Novel genetic score model (cut off value of 1.5)
Number of subjects: 160
Study: 27160356

Group type: EXPERIMENTAL
Intervention: MRI at Week 14 post-NACRT
Number of subjects: 35
Study: 27160692

Group type: EXPERIMENTAL
Intervention: Positive Aspergillus culture (PAC) group
Number of subjects: 85

Group type: COMPARATOR
Intervention: Only positive galactomannan (OPG) group
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: PAC group
Number of subjects: 85

Group type: COMPARATOR
Intervention: OPG group
Number of subjects: 85
Study: 27160944

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0
Study: 27160947

Group type: EXPERIMENTAL
Intervention: Apalutamide 240mg/d
Number of subjects: 51
Study: 27161025

Group type: EXPERIMENTAL
Intervention: Breakfast eating
Number of subjects: 75

Group type: COMPARATOR
Intervention: Breakfast skipping
Number of subjects: 75
Study: 27161178

Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 5171

Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.75 mg
Number of subjects: 5171

Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg and 0.75 mg
Number of subjects: 5171
Study: 27161848

Group type: EXPERIMENTAL
Intervention: Sarcopenic obesity (SO) in patients with COPD
Number of subjects: 2548

Group type: COMPARATOR
Intervention: Normal body composition in patients with COPD
Number of subjects: 2548
Study: 27161867

Group type: EXPERIMENTAL
Intervention: Prior lateral meniscectomy
Number of subjects: 1205

Group type: EXPERIMENTAL
Intervention: Current grade 3 to 4 trochlear articular cartilage changes
Number of subjects: 1205

Group type: COMPARATOR
Intervention: Meniscal or articular cartilage pathologic changes
Number of subjects: 1205
Study: 27161955

Group type: EXPERIMENTAL
Intervention: Dihydropyrimidine dehydrogenase (DPD) activity in PBMCs
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Thymidylate synthase (TS) activity in PBMCs
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: DHU : U plasma ratio
Number of subjects: 20
Study: 27162131

Group type: EXPERIMENTAL
Intervention: (18)F-fluorocholine (18F-FCH) uptake in ipsilateral symptomatic carotid plaques
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: (18)F-fluorocholine (18F-FCH) uptake
Number of subjects: 10
Study: 27162212

Group type: EXPERIMENTAL
Intervention: Angiographic Core Laboratory (ACL) assessment
Number of subjects: 329

Group type: COMPARATOR
Intervention: Clinical Event Committee (CEC) assessment
Number of subjects: 329

Group type: COMPARATOR
Intervention: Local Investigators (LIs) assessment
Number of subjects: 329
Study: 27162226

Group type: EXPERIMENTAL
Intervention: Prostaglandin analogues (PGAs)
Number of subjects: 35
Study: 27162632

Group type: EXPERIMENTAL
Intervention: Riociguat
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27163539

Group type: EXPERIMENTAL
Intervention: Renal transplanted patients with pretransplant cancer
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group (European patients without pretransplant cancer)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group (entire renal transplanted population in Uppsala)
Number of subjects: 95
Study: 27163758

Group type: EXPERIMENTAL
Intervention: FIRM only (group 1)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: FIRM + PVAI (group 2)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: PVAI + posterior wall + non-PV trigger ablation (group 3)
Number of subjects: 113
Study: 27163948

Group type: EXPERIMENTAL
Intervention: Patient Blood Management (PBM) program including preoperative optimization of hemoglobin levels, blood-sparing techniques, and standardization of transfusion practice.
Number of subjects: 129719

Group type: EXPERIMENTAL
Intervention: Patient Blood Management (PBM) program
Number of subjects: 129719
Study: 27164015

Group type: EXPERIMENTAL
Intervention: Phenylephrine administration
Number of subjects: 50
Study: 27165419

Group type: EXPERIMENTAL
Intervention: Cardiopulmonary exercise testing (CPET)
Number of subjects: 34
Study: 27165613

Group type: EXPERIMENTAL
Intervention: Accelerated radiotherapy with carbogen and nicotinamide (ARCON)
Number of subjects: 345

Group type: COMPARATOR
Intervention: Accelerated radiotherapy alone (AR)
Number of subjects: 345
Study: 27165710

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 4935

Group type: COMPARATOR
Intervention: Heparin±GPI
Number of subjects: 4935
Study: 27165786

Group type: EXPERIMENTAL
Intervention: Mecillinam (400 mg pivmecillinam hydrochloride three times a day for 7 days)
Number of subjects: 20
Study: 27165892

Group type: EXPERIMENTAL
Intervention: Visuospatial memory domain deficit
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Language domain deficit
Number of subjects: 74
Study: 27165960

Group type: COMPARATOR
Intervention: Post-neonatal arterial ischemic stroke children with severe contralesional hand motor deficit
Number of subjects: 37

Group type: COMPARATOR
Intervention: Post-neonatal arterial ischemic stroke children with good manual dexterity
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Contralesional hand performance
Number of subjects: 37
Study: 27166296

Group type: EXPERIMENTAL
Intervention: Polysomnography (PSG)
Number of subjects: 15
Study: 27166673

Group type: EXPERIMENTAL
Intervention: Bevacizumab monotherapy
Number of subjects: 35
Study: 27167022

Group type: EXPERIMENTAL
Intervention: Single ventricle lesions after arch reconstruction
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Single ventricle lesions with gothic arch geometry
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Single ventricle lesions with right ventricle-pulmonary artery shunt
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Single ventricle lesions with aortic atresia
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Single ventricle lesions with recoarctation
Number of subjects: 326
Study: 27167056

Group type: EXPERIMENTAL
Intervention: iSYS
Number of subjects: 911

Group type: EXPERIMENTAL
Intervention: LIAISON XL
Number of subjects: 911

Group type: EXPERIMENTAL
Intervention: IMMULITE
Number of subjects: 911

Group type: EXPERIMENTAL
Intervention: IGFI RIACT
Number of subjects: 911

Group type: EXPERIMENTAL
Intervention: Mediagnost ELISA
Number of subjects: 911

Group type: EXPERIMENTAL
Intervention: Mediagnost RIA
Number of subjects: 911

Group type: COMPARATOR
Intervention: All assays
Number of subjects: 911
Study: 27167058

Group type: EXPERIMENTAL
Intervention: Intraoperative fluid challenge with 10 ml/kg of 0.9% normal saline
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Dynamic preload variables
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Vascular tone variables
Number of subjects: 31
Study: 27167209

Group type: EXPERIMENTAL
Intervention: Oral macrolides after an initial 4-week IV amikacin and cefoxitin (or imipenem) treatment
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Oral macrolides after an initial 2-week IV amikacin and cefoxitin (or imipenem) treatment
Number of subjects: 71